One Substance, Multiple Legal Realities: Classification Cascades in the Psychedelic Medicine Transition

Psilocybin currently holds six contradictory legal classifications across different jurisdictions, including Schedule I in the US, Breakthrough Therapy designation from the FDA, legal therapeutic use in Oregon and Colorado, Schedule 8 medical use in Australia, and pending rescheduling review. This fragmentation creates a classification cascade—a disruption propagating through administrative, clinical, and economic channels. Analysis of 44 regulatory events across 21 countries (1992–2025) shows a sharp inflection after the 2018 FDA Breakthrough Therapy Designation. Psilocybin-depression research grew at 58.6% annually (2015–2025), and total psilocybin publications increased 54-fold from 12 (2000) to 656 (2025).

Study at a glance

Abstract

Psilocybin simultaneously holds six contradictory legal classifications across jurisdictions: Schedule I (US federal), Breakthrough Therapy (FDA), legal therapeutic use (Oregon, Colorado), Schedule 8 medical use (Australia), and pending rescheduling review (DEA/HHS). This regulatory fragmentation constitutes a classification cascade—a multi-stage disruption propagated through administrative, clinical, and economic channels when a single substance is reclassified unevenly across overlapping governance systems. Using four complementary empirical strategies, I document the cascade’s progression: (i) a 21-country policy panel tracking 44 psychedelic regulatory events across 6 substance categories (1992–2025), revealing a sharp inflection at the 2018 FDA Breakthrough Therapy Designation; (ii) PubMed publication data extracted via NCBI E-utilities API showing psilocybin-depression research growing at 58.6% compound annual growth rate (2015–2025)—the fastest in psychedelic medicine, with total psilocybin publications increasing 54-fold from 12 (2000) to 656 (2025); (iii) trade flow analysis using difference-in-differences designs showing that botanical pharmaceutical imports (HS 1211) diverge sharply from control commodities following cannabis/psychedelic policy reforms, with estimates ranging from +67% to +97% in liberalizing countries; and (iv) FDA pipeline analysis documenting COMP360’s consecutive Phase 3 successes (MADRS −3.6 and −3.8 versus placebo, both p < 0.001) alongside simultaneous political vetoes. The findings demonstrate that classification cascades—previously documented in healthcare billing (Tamba 2026)—extend to substance regulation, where they generate measurable distortions in research output, trade flows, clinical access, and enforcement patterns. I introduce the concept of the classification split—a state in which a single entity simultaneously occupies contradictory categories across overlapping governance systems—as a distinct and increasingly prevalent form of regulatory failure. As psilocybin approaches FDA approval (NDA expected Q4 2026), the cascade documented here is accelerating rather than resolving. "Note: The original version (v1) of this preprint was deposited on 15 April 2026, prior to the U.S. Executive Order on psychedelic therapies signed on 18 April 2026. Version v2 incorporates subsequent editorial revisions."